Entrectinib Phase 1/2 Study in Pediatric Solid Tumors and CNS Tumors Initiated
A Phase 1/2 study of Entrectinib in pediatric patients with advanced solid tumors and CNS tumors has been initiated.
Asset / Drug
Drug and asset intelligence for Entrectinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.